Minimization of cisplatin nephrotoxicity in high-risk patients

Nephron

Volumn 73, Issue 2, 1996, Pages 325-326

  Donadio, Carlo ^a   Lucchesi, Annalisa ^a   Gadducci, Angiolo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; CASE REPORT; FEMALE; HIGH RISK PATIENT; HUMAN; LETTER; MALAISE; NEPHROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; VOMITING;

ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FUNCTION TESTS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RISK;

EID: 0030014607     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189066     Document Type: Article

References (7)

1. Bennett WM, Elzinga LW, Porter GA: Tubu-lointcrstitial disease and toxic nephropathy; in Brenner BM. Rector EC Jr (eds): The Kidney, ed 4. Philadelphia. Saunders. 1991. vol 2. pp 1430-1496.
2. Bianchi C. Donadio C. Tramonti G: Noninva-sive methods for the measurement of total renal function. Nephron 1981;28:53-57.
3. Stark JJ. Howell SB: Nephrotoxicity of β-platinum (II) dichlorodiammine. Clin Pharmacol Ther 1978;23:461-466.
4. Ozols RF, Corden BJ. Jacob J. Wesley MN. Ostchega Y. Young RC: High-dose cisplatin in hypertonic saline. Ann Intern Med 1984:100: 19-24.
5. Salem P. Khalyl M. Jabboury K. Hashimi L: ra-Diamminedichloroplatinum (II) by 5-day continuous infusion: A new schedule with minimal toxicity. Cancer 1984:53:837-840.
6. Jones BR. Bhalla RB. Mladck J. Kalcya RN. Gralla RJ. Alcock NW, Schwartz MK. Young CW. Reidenberg MM: Comparison of methods of evaluating nephrotoxicity of m-platinum. Clin Pharmacol Ther 1980:27:557-562.
7. Verplanke AJW. Herber RFM. de Wit R. Veenhof CHN: Comparison of renal function parameters in the assessment of cisplatin-in-duced nephrotoxicity. Nephron 1994:66:267-272.